Radioimmunoassay for nanogram quantities of DNA

Leon, Shalom A.; Green, A.; Yaros, M.J.; Shapiro, Barry A.

doi:10.1016/0022-1759(75)90106-4

Cited by 62 publications

(52 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although our study confirms the findings of previous studies, in which a wide range of plasma cfDNA levels was demonstrated among different patient groups, [6][7][8][18][19][20] we also found that cfDNA levels were significantly different in patients with SCD during steady state when compared with individuals with sickle cell trait and healthy controls. These data may potentially be useful in clinical practice to differentiate post-packed red cell transfusion SCD patients from individuals with sickle cell trait, as such differentiation is currently based mainly on reliable transfusion history, which often is unknown or not available.…”

Section: Commentsupporting

confidence: 91%

“…Later studies on circulating nucleic acids were mainly focused on autoimmune diseases. 6 The profound implication of circulating nucleic acids in diagnostic medicine became recognized only some 30 years later, when Leon et al 7 demonstrated elevated circulating cell-free nucleic acid levels in cancer patients when compared with healthy controls and a generally poorer survival of cancer patients with higher circulating nucleic acid level after therapies. This finding has opened up new avenues to use cell-free DNA (cfDNA) for noninvasive diagnosis and monitoring.…”

Section: 3mentioning

confidence: 99%

“…Circulating nucleic acids in plasma/serum were discovered by Mandel and Metais 5 in 1947, and it was not until 1975 that Leon et al 6 were able to quantitate circulating plasma cfDNA. Later studies 7,9,12,17 were mainly focused on using circulating cfDNA as a potentially useful diagnostic and prognostic marker in a variety of clinical conditions, including cancer, pregnancy, physical trauma, and solid organ transplant.…”

Section: Commentmentioning

confidence: 99%

See 2 more Smart Citations

Circulating Cell-Free DNA in Sickle Cell Disease: Is It a Potentially Useful Biomarker?

Al-Humood

Zueriq

Al-Faris

et al. 2014

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.—Vascular occlusion in sickle cell disease causes increased levels of plasma cell-free DNA as a result of cell death and tissue damage. Objectives.—This study investigates plasma cell-free DNA concentrations in sickle cell disease patients, and aims at exploring the significance of plasma cell-free DNA as a potential biomarker in predicting its complications. Design.—Plasma cell-free DNA levels were measured using real-time quantitative polymerase chain reaction to quantitatively measure β-globin gene in blood samples from 57 sickle cell disease patients with acute vaso-occlusive crisis, 42 patients in steady state, 16 individuals with sickle cell trait, and 40 healthy controls. Results.—Plasma cell-free DNA level was significantly elevated in samples from patients with acute vaso-occlusive crisis when compared with those in steady state (P = .002), and was significantly higher both in crisis and in steady state when compared with individuals with sickle cell trait and healthy controls (P < .001). There was no difference in cell-free DNA levels between individuals with sickle cell trait and healthy controls. There was no association between plasma cell-free DNA levels and various clinical complications of sickle cell disease and comorbidity. Conclusions.—Plasma cell-free DNA, as quantified by polymerase chain reaction amplification of the β-globin and human telomerase reverse transcriptase genes, is increased in sickle cell disease patients in vaso-occlusive crisis and in steady state compared with individuals with sickle cell trait and healthy controls, and may be used as a tool to diagnose and monitor the sickle cell crisis and differentiate post–packed red cell transfusion sickle cell disease patients from individuals with sickle cell trait.

show abstract

Section: Commentsupporting

confidence: 91%

Section: 3mentioning

confidence: 99%

Section: Commentmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Cell-Free DNA in Sickle Cell Disease: Is It a Potentially Useful Biomarker?

Al-Humood

Zueriq

Al-Faris

et al. 2014

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…The presence of circulating, cell-free nucleic acids (ctNAs) in blood has been described since the middle of the last century (Leon et al, 1977;Mandel and Metais, 1948;Stroun et al, 1989). Most healthy individuals (over 90%) have a small amount of cellfree DNA ([cfDNA] 25 ng/ml whole blood).…”

Section: Circulating Nucleic Acids (Ctnas)mentioning

confidence: 99%

Liquid biopsies: tumour diagnosis and treatment monitoring

Pham

2016

Biomed Res Ther

View full text Add to dashboard Cite

Abstract-Cancer is a disease with high evolutionary, i.e., malignant, characteristics that change under selective pressure from therapy. Characterization based on molecular or primary tumor properties or clinicopathological staging does not fully reflect the state of cancer, especially when cancer cells metastasize. This is the major reason for failure of cancer treatment. Currently, there is an urgent need for new approaches that allow more effective, but less invasive, monitoring of cancer status, thereby improving the efficacy of treatments. With recent technological advances, "liquid biopsies," the isolation of intact cells or analysis of components that are secreted from cells, such as nucleic acids or exosomes, could be implemented easily. This approach would facilitate real-time monitoring and accurate measurement of critical biomarkers. In this review, we summarize the recent progress in the identification of circulating tumor cells using new high-resolution approaches and discuss new circulating tumor nucleic acid-and exosome-based approaches. The information obtained through liquid biopsies could be used to gain a better understanding of cancer cell invasiveness and metastatic competence, which would then benefit translational applications such as personalized medicine.

show abstract

“…Гипотезам о некротическом и апоптотическом происхождении цирДНК противоречат данные о 90%-ном снижении уровня ДНК в плазме онкологических больных после окончания курса радиотерапии [27]. Известно, что радиация индуцирует некроз (или апоптоз, в зависимости от дозы облучения), и такая обработка должна была бы приводить к повышению концентрации дезоксирибонуклеиновых кислот [28].…”

Section: происхождение цирднк в результате некроза (рис 1а)unclassified

Generation of blood circulating DNA: the sources, peculiarities of circulation and structure

Bryzgunova

Laktionov

2015

BIOMED KHIM

View full text Add to dashboard Cite

Внеклеточные нуклеиновые кислоты (внНК) в циркуляции как здоровых, так и больных людей были впервые описаны в 1948 г., однако оставались без внимания до середины 60-х годов прошлого века. внНК особенно интенсивно исследуются в последние 5 лет. Основное внимание уделяется исследованию внНК как источнику диагностического материала; однако механизмы генерации внеклеточных нуклеиновых кислот, а также механизмы, обеспечивающие их долговременную циркуляцию в кровотоке, однозначно не установлены. По данным одних авторов, основным источником циркулирующих дезоксирибонуклеиновых кислот в крови (цирДНК) являются процессы некроза и апоптоза, другие ссылаются на возможную секрецию нуклеиновых кислот как здоровыми, так и опухолевыми клетками. Известно, что цирДНК могут циркулировать в крови в течение длительного времени, ускользая от действия ДНК-гидролизующих ферментов крови и, по-видимому, находясь в составе надмолекулярных комплексов. В этом обзоре представлены данные разных авторов и приведены доказательства в пользу всех предложенных теорий появления цирДНК, описаны особенности строения цирДНК, а также факторы, влияющие на время циркуляции ДНК в крови.Ключевые слова: циркулирующая ДНК, апоптоз, некроз, активная секреция, ДНКазы, метилирование.

show abstract

Radioimmunoassay for nanogram quantities of DNA

Cited by 62 publications

References 24 publications

Circulating Cell-Free DNA in Sickle Cell Disease: Is It a Potentially Useful Biomarker?

Circulating Cell-Free DNA in Sickle Cell Disease: Is It a Potentially Useful Biomarker?

Liquid biopsies: tumour diagnosis and treatment monitoring

Generation of blood circulating DNA: the sources, peculiarities of circulation and structure

Contact Info

Product

Resources

About